2nd email to Dr. Anthony Fiore ...

Previous emal can be found here

Progress Toward Understanding Infection-Associated Chronic Conditions and Illnesses
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/34076105

Is the latest announcement from the CDC just more SMOKE AND MIRRORS?? 

Where then is the Manhattan Project to find a cure for CHRONIC LYME???

---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: "afiore@cdc.gov" <afiore@cdc.gov>
Cc: "dpd1@cdc.gov" <dpd1@cdc.gov>, "Matthew_Kuehnert@mtf.org" <Matthew_Kuehnert@mtf.org>, "ebelay@cdc.gov" <ebelay@cdc.gov>, "richard.bradbury@jcu.edu.au" <richard.bradbury@jcu.edu.au>
Date: 11/20/2025 8:21 AM EST
Subject: Re: Progress Toward Understanding Infection-Associated Chronic Conditions and Illnesses
 
 
Dr. Fiore,
 
Forty-eight  years ago Dr. Allen Steere identified chronic Lyme disease which should have set off a red flag prompting an immediate search for better antimicrobials but then did a 180° as he became principal investigator (PI) of the Phase 3 clinical trial for the first Lyme disease vaccine. So all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. Apparently, a chronic relapsing seronegative disease did not fit the business model of patent royalties, vaccine development and pharmaceutical profits. This set the stage for long-term treatment denial and unimaginable pain and suffering around the world and has been ongoing for over three decades.
 
This is what Steere was reporting in 1977:
 
Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. (1977)
 
Steere AC, Malawista SE, Snydman DR, Shope RE, Andiman WA, Ross MR, Steele FM.
 
https://www.ncbi.nlm.nih.gov/pubmed/836338
 
Excerpt:
 
“The best treatment for this illness is not clear. Some physicians have reported that penicillin or tetracycline results in disappearance of the skin lesion (41,42), but others find antibiotics ineffective. Four of the patients with expanding skin lesions received penicillin but still developed arthritis.”
 
 
Dr. Fiore…
 
In an attempt to set the record straight with the "learned" AI viewpoint of Lyme disease, I spent some time with Google’s Gemini AI this morning and gave "it" a lesson...
 
 
Carl Tuttle: Imagine for a moment that a new bacterial disease resistant to all current antimicrobials hits the United States. Would our public health officials (CDC) rush to create a vaccine or would they initiate a Manhattan Project to find a cure (effective antimicrobials)?
 
Response from Google’s Gemini AI:
 
In the scenario of a new bacterial disease resistant to all current antimicrobials, U.S. public health officials, including the CDC, would pursue a dual strategy, initiating efforts to accelerate the development of both a vaccine and a cure (novel antimicrobials). They would likely organize a "Manhattan Project-style" effort that coordinates public and private sector resources, similar to "Operation Warp Speed" for COVID-19, to dramatically cut development time for both types of countermeasures. 
 
Rushing to Create a Vaccine
 
Vaccines are considered a critical and highly effective tool for combating antimicrobial resistance (AMR) because they prevent infections from occurring in the first place, thereby reducing the need for antibiotics and slowing the spread of resistant strains. The development of a vaccine would be a high priority for the following reasons: 
 
Prevention: A vaccine offers long-lasting, population-wide protection and indirect protection through herd immunity, which is an efficient public health approach to halt the spread of a disease.
Long-term Solution: Unlike antibiotics, which bacteria can develop resistance to relatively quickly, vaccine resistance is far less common and typically evolves much more slowly.
Established Framework: Advances in vaccine technology, such as mRNA platforms highlighted during the COVID-19 pandemic, have demonstrated the potential for rapid vaccine development in a crisis, making it a feasible strategy.
Existing Strategy: The U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) explicitly includes accelerating research on new vaccines as a key strategic goal.  

Initiating a Manhattan Project to Find a Cure
 
Simultaneously, a massive, coordinated effort to discover and develop new effective antimicrobials would be launched. This is essential for treating individuals already infected or those who cannot be vaccinated, such as the immunocompromised. 
 
Immediate Treatment: A cure is needed for those currently suffering from the infection, as existing options would be non-existent in this scenario.

Addressing the Core Problem: The ongoing challenge of antibiotic resistance is a major public health priority, and federal agencies are continuously working to accelerate the research and development pipeline for new drugs.

Coordinated Effort: This "Manhattan Project" (or "Operation Warp Speed" equivalent) would pool resources from private pharmaceutical companies, government agencies (like the CDC, FDA, NIH, and BARDA), and the military to de-risk and accelerate the research and development pipeline for new antibiotics and other therapeutics. 
The response would not be an either/or choice. The most effective public health strategy would involve an intensive, coordinated approach on both fronts: developing a vaccine to prevent new infections and discovering new antimicrobials to treat existing ones. Both are considered critical tools in a comprehensive strategy to combat an existential threat of this nature. 
 
 
Carl Tuttle: Well, that didn’t happen when Lyme disease was discovered because the rush to create a vaccine led to the deliberate mishandling of the disease. Here is what took place: 
 
1. Produce a two-tier antibody testing algorithm where first line screening tests (Elisa) fail to detect 60% of infections. Those patients who do test positive will be allowed the second more sensitive test (Western blot) but design the test with strict criteria (Case definition) so as to rule out 90% keeping infection numbers artificially low.
 
Note: Do not consider a false negative Elisa as they do not exist and remember; Western blot tests are only ordered after a positive Elisa. Disregard any (outside) studies proving poor testing reliability and certainly do not listen to any patient complaints.
   
2. Fund only those studies through institutions with researchers that have a bias against persistent infection. It is imperative that these researchers are retained exclusively to continue the pier review process and publishing of each other’s studies. There must be no acceptance of outside studies.

3. Maintain a belief that all stages of infection, acute through late stage are easily cured with a standard two week treatment guidelineand turn the disease into a syndrome when patients complain of persistent debilitating symptoms after unsuccessful treatment. Insist that persistent infection cannot exist even though antibody tests can only identify at best a past infection.

4. If a culture tests hould be developed which is the gold standard for many bacterial infections do not recognize this test and insist it is not government approved.

5. Create a map depicting limited territories where the infection is present. Use an existing institution with a bias against persistent infection to manage the data. Employ the services of a well known public relations firm to announce the map so as to maintain the belief that mainstream healthcare has “got everything under control.”

6. Define the disease exclusively as a zoonotic illness and disregard congenital and gestational transfer cases or transfer between sexually active couples.

7. No need to screen the blood supply for this pathogen.

8. Primate studies proving persistent infection after standard treatment will be ignored.

9. Create a foundation to promote the disinformation campaign and staff the foundation with the same researchers with a bias against persistent infection.
 
 
Response from Google’s Gemini AI:
 
 
The nine points you've outlined reflect significant, long-standing controversies and criticisms that have been leveled against the mainstream medical establishment's (including the CDC's and IDSA's) approach to Lyme disease diagnosis and treatment. These points represent a perspective held by patient advocacy groups and some medical professionals, most notably those associated with the International Lyme and Associated Diseases Society (ILADS), who argue that the disease's official handling has led to a major public health failure and a "disinformation campaign". 
 
 
Carl Tuttle: Suppressing evidence of antibiotic resistance is not collaboration, it is collusion. See the following references: https://drive.google.com/file/d/1S7ynlfLzmNCjKpPHQuVsa0-pmG-7nf23/view
 
Response from Google’s Gemini AI:
 
Critics of the official handling of Lyme disease by the CDC, NIH, and IDSA argue that the public health response has been influenced by a desire to control the narrative, potentially suppressing evidence of persistent infection and limitations of current diagnostics and treatments. Allegations center on controversies including diagnostic test accuracy, persistent infection after treatment, research funding and peer review, treatment guidelines, and ignoring evidence [3, 5]. Patient advocacy groups and some researchers characterize this situation as a coordinated effort to control the disease's definition and management, which they describe as collusion. You can find more information about these criticisms from patient advocacy groups. 
 
According to a Change.org petition update, the Infectious Diseases Society of America (IDSA) guidelines on Lyme disease have been subject to criticism regarding perceived bias and suppression of dissenting scientific views. These criticisms also raise questions about the reliability of the standard two-tiered testing protocol and the recognition of persistent infection after treatment. For more details, visit Change.org. 
 
 
 
Carl Tuttle
Independent Researcher
Hudson, NH
 
Lyme Disease: Call for a “Manhattan Project” to Combat the Epidemic

Raphael B. Stricker, Lorraine Johnson 
 
Published: January 02, 2014 
http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003796